GLP-1RA Cuts Obesity-Linked Cancer Risk 41% in 229,000 Adults
Updated
Updated · Oncodaily · Aug 4
GLP-1RA Cuts Obesity-Linked Cancer Risk 41% in 229,000 Adults
3 articles · Updated · Oncodaily · Aug 4
Summary
A target-trial emulation of more than 229,000 obese, nondiabetic adults linked GLP-1RA use to a 41% lower rate of obesity-associated cancers than lifestyle modification alone.
The study reported a hazard ratio of 0.5, adding evidence that GLP-1 drugs may deliver benefits beyond weight loss for patients with prior cancer or other high-risk features.
Ashish M. Kamat called the Annals of Oncology findings a new data point beyond lifestyle counseling, while Petros Grivas said the drugs may have broader benefits alongside screening and genetic-risk assessment.
The result fits a wider 2026 research trend tying GLP-1 medicines such as Ozempic and Wegovy to lower cancer risk and recurrence, though experts still say randomized trials are needed to confirm causation.